MCID: AMY004
MIFTS: 64

Amyloidosis

Categories: Metabolic diseases, Genetic diseases, Rare diseases, Neuronal diseases, Bone diseases, Cardiovascular diseases, Nephrological diseases, Blood diseases

Aliases & Classifications for Amyloidosis

Summaries for Amyloidosis

MedlinePlus : 41 amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. the deposits can collect in organs such as the kidney and heart. this can cause the organs to become stiff and unable to work the way they should. there are three main types of amyloidosis: primary - with no known cause secondary - caused by another disease, including some types of cancer familial - passed down through genes symptoms can vary, depending upon which organs are affected. treatment depends on the type of amyloidosis you have. the goal is to help with symptoms and limit the production of proteins. if another disease is the cause, it needs to be treated.

MalaCards based summary : Amyloidosis, also known as amyloid disease, is related to muckle-wells syndrome and familial cold-induced inflammatory syndrome 1, and has symptoms including inguinal hernia, ureteral stenosis and renal insufficiency. An important gene associated with Amyloidosis is TTR (Transthyretin), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Exenatide and Pramlintide have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 An acquired metabolic disease that involves abnormal deposited of amyloid proteins in organs and/or tissues.

Wikipedia : 72 Amyloidosis is a group of diseases in which abnormal protein, known as amyloid fibrils, builds up in... more...

Related Diseases for Amyloidosis

Diseases in the Amyloidosis family:

Amyloidosis, Hereditary, Transthyretin-Related Al Amyloidosis
Amyloidosis Aa Hereditary Amyloidosis
Primary Localized Amyloidosis Ah Amyloidosis

Diseases related to Amyloidosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 509)
id Related Disease Score Top Affiliating Genes
1 muckle-wells syndrome 33.3 MEFV NLRP3 TNFRSF1A
2 familial cold-induced inflammatory syndrome 1 31.9 MEFV NLRP3 TNFRSF1A
3 amyloidosis nodular localized cutaneous 31.7 APOA1 B2M MEFV SAA1 SAA2 SAA4
4 familial mediterranean fever, ad 31.2 MEFV NLRP3 SAA1 TNFRSF1A
5 calcinosis 29.7 B2M CST3 LYZ
6 chronic myelomonocytic leukemia 28.8 B2M CST3 TTR
7 pick disease 28.2 APOE APP BACE1
8 amyloidosis, hereditary, transthyretin-related 12.4
9 al amyloidosis 12.4
10 primary cutaneous amyloidosis 12.4
11 amyloidosis, finnish type 12.3
12 amyloidosis, familial visceral 12.3
13 amyloidosis aa 12.3
14 hereditary amyloidosis 12.3
15 amyloidosis, primary localized cutaneous, 1 12.2
16 familial amyloidosis, finnish type 12.1
17 amyloidosis, primary localized cutaneous, 2 12.1
18 wild type attr amyloidosis 12.0
19 aapoaii amyloidosis 12.0
20 primary localized amyloidosis 11.9
21 cerebral amyloid angiopathy 11.9
22 ah amyloidosis 11.9
23 alect2 amyloidosis 11.9
24 multiple myeloma 11.9
25 wild type abeta2m amyloidosis 11.9
26 aapoai amyloidosis 11.9
27 afib amyloidosis 11.8
28 nodular cutaneous amyloidosis 11.8
29 variant abeta2m amyloidosis 11.8
30 aapoaiv amyloidosis 11.8
31 leptomeningeal amyloidosis 11.8
32 amyloidosis cutis dyschromia 11.8
33 macular amyloidosis 11.8
34 lichen amyloidosis 11.8
35 cerebral amyloid angiopathy, dutch, italian, iowa, flemish, arctic variants 11.7
36 familial oculoleptomeningeal amyloidosis 11.7
37 amyloidosis beta2m 11.7
38 amyloidosis of gingiva and conjunctiva with intellectual disability 11.7
39 prp systemic amyloidosis 11.7
40 amyloidosis bronchopulmonary 11.6
41 apoa1-related familial visceral amyloidosis 11.6
42 fga-related familial visceral amyloidosis 11.6
43 lyz-related familial visceral amyloidosis 11.6
44 corneal dystrophy, gelatinous drop-like 11.6
45 pigmentary disorder, reticulate, with systemic manifestations, x-linked 11.5
46 dementia, familial danish 11.4
47 lattice corneal dystrophy type ii 11.3
48 familial mediterranean fever, ar 11.3
49 periodic fever, familial 11.2
50 macroglossia 11.1

Comorbidity relations with Amyloidosis via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Kidney Failure
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Amyloidosis:



Diseases related to Amyloidosis

Symptoms & Phenotypes for Amyloidosis

Human phenotypes related to Amyloidosis:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 inguinal hernia 32 occasional (7.5%) HP:0000023
2 ureteral stenosis 32 occasional (7.5%) HP:0000071
3 renal insufficiency 32 frequent (33%) HP:0000083
4 nephrotic syndrome 32 frequent (33%) HP:0000100
5 everted lower lip vermilion 32 hallmark (90%) HP:0000232
6 protruding ear 32 hallmark (90%) HP:0000411
7 abnormality of vision 32 occasional (7.5%) HP:0000504
8 hyperkeratosis 32 occasional (7.5%) HP:0000962
9 corneal dystrophy 32 hallmark (90%) HP:0001131
10 hemiparesis 32 occasional (7.5%) HP:0001269
11 redundant skin 32 hallmark (90%) HP:0001582
12 abnormality of the cardiovascular system 32 frequent (33%) HP:0001626
13 talipes equinovarus 32 occasional (7.5%) HP:0001762
14 alopecia of scalp 32 occasional (7.5%) HP:0002293
15 abnormality of the immune system 32 hallmark (90%) HP:0002715
16 impaired pain sensation 32 occasional (7.5%) HP:0007328
17 generalized hyperpigmentation 32 hallmark (90%) HP:0007440
18 aplasia/hypoplasia of the skin 32 hallmark (90%) HP:0008065
19 facial palsy 32 hallmark (90%) HP:0010628
20 morphological abnormality of the gastrointestinal tract 32 frequent (33%) HP:0012718
21 palpebral edema 32 hallmark (90%) HP:0100540
22 glomerulopathy 32 hallmark (90%) HP:0100820

MGI Mouse Phenotypes related to Amyloidosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 BACE1 CST3 FGA GSN IAPP IL31RA
2 hematopoietic system MP:0005397 10.25 B2M FGA GSN IAPP IL31RA LYZ
3 cellular MP:0005384 10.22 TNFRSF1A APOA1 APOE APP B2M BACE1
4 immune system MP:0005387 10.18 APOE APP B2M FGA GSN IAPP
5 endocrine/exocrine gland MP:0005379 10.11 APOA1 APOE B2M FGA GSN LYZ
6 integument MP:0010771 10.1 APOA1 APOE APP B2M BACE1 FGA
7 liver/biliary system MP:0005370 9.91 TNFRSF1A APOA1 APOE B2M FGA LYZ
8 no phenotypic analysis MP:0003012 9.7 APOE APP BACE1 LYZ OSMR TNFRSF1A
9 reproductive system MP:0005389 9.61 APOE APP B2M CST3 FGA GSN
10 skeleton MP:0005390 9.28 APOE FGA GSN IAPP IL31RA LYZ

Drugs & Therapeutics for Amyloidosis

Drugs for Amyloidosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 504)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Exenatide Approved, Investigational Phase 4,Phase 3 141758-74-9 15991534
2
Pramlintide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 151126-32-8
3
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
6
Ramipril Approved Phase 4 87333-19-5 5362129
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Pravastatin Approved Phase 4 81093-37-0 54687
9
Simvastatin Approved Phase 4,Phase 2 79902-63-9 54454
10
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
11
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
12
Clozapine Approved Phase 4 5786-21-0 2818
13
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
14
Insulin Glargine Approved Phase 4 160337-95-1
15
Donepezil Approved Phase 4,Phase 2,Phase 3 120014-06-4 3152
16
Dopamine Approved Phase 4,Phase 1,Phase 2 51-61-6, 62-31-7 681
17
Galantamine Approved Phase 4 357-70-0 9651
18
Memantine Approved, Investigational Phase 4,Phase 3 19982-08-2 4054
19
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
20
Amlodipine Approved Phase 4 88150-42-9 2162
21
Insulin Aspart Approved Phase 4,Phase 2,Phase 1 116094-23-6 16132418
22
Insulin Detemir Approved Phase 4 169148-63-4 5311023
23
Insulin Lispro Approved Phase 4,Phase 2,Phase 1 133107-64-9
24
Prazosin Approved Phase 4 19216-56-9 4893
25
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
26
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
27 Racepinephrine Approved Phase 4
28
Citalopram Approved Phase 4 59729-33-8 2771
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
30
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
31
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
32
Angiotensin II Investigational Phase 4,Phase 2,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
33
Corticosterone Experimental Phase 4,Phase 2,Phase 1,Early Phase 1 50-22-6 5753
34
Iodine Investigational Phase 4 7553-56-2 807
35
Huperzine A Investigational Phase 4 102518-79-6
36 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
37 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
40 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Adrenergic Agents Phase 4,Phase 2
43 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1,Phase 2
45 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
47 Anti-Obesity Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Appetite Depressants Phase 4,Phase 3,Phase 2,Phase 1
49 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
50 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 790)

id Name Status NCT ID Phase Drugs
1 The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease Completed NCT00046358 Phase 4 Lovostatin;Ibuprofen
2 Trial of Carvedilol in Alzheimer's Disease Completed NCT01354444 Phase 4 Carvedilol;Placebo
3 Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Completed NCT02681172 Phase 4 Neuraceq (florbetaben 18F)
4 Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's Completed NCT00980785 Phase 4 Ramipril;Placebo
5 The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria Completed NCT00674596 Phase 4 ramipril
6 Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus Completed NCT00982358 Phase 4 Valsartan
7 Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Completed NCT00303277 Phase 4 simvastatin;pravastatin
8 Myocardial Protection of Exenatide in AMI Completed NCT01580514 Phase 4 exenatide BYETTA® (Amylin-Lilly);Saline
9 Continuous Subcutaneous Infusion of Pramlintide and Insulin Completed NCT00291772 Phase 4 Pramlintide
10 A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes Completed NCT00502138 Phase 4 Continuous Pramlintide infusion
11 Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus Completed NCT00442767 Phase 4 Pramlintide acetate
12 Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes Completed NCT00212290 Phase 4 pioglitazone;nateglinide;placebo
13 The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes Completed NCT00950677 Phase 4 Byetta (exenatide);Symlin (pramlintide)
14 Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia Completed NCT00690235 Phase 4 Pramlintide;Placebo
15 A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes Completed NCT00240253 Phase 4 pramlintide acetate
16 Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease Completed NCT00551161 Phase 4 memantine
17 Double Blind Atorvastatin Amlodipine Study Completed NCT00159718 Phase 4 amlodipine;atorvastatin
18 Study to Determine the Digestive and Physiological Effects of an Extract From Bran in Healthy Men and Women Completed NCT01073969 Phase 4
19 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
20 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Recruiting NCT01683825 Phase 4 F-18 florbetapir PET
21 The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis Recruiting NCT03040427 Phase 4 F-18 florbetapir
22 Effects of Brain Beta-Amyloid on Postoperative Cognition Recruiting NCT01606488 Phase 4 Florbetapir F 18 (18F-AV-45)
23 Prazosin and CSF Biomarkers in mTBI Recruiting NCT03221751 Phase 4 prazosin hydrochloride;placebo
24 Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients Recruiting NCT00842920 Phase 4 Simvastatin;Placebo
25 SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Recruiting NCT02951559 Phase 4
26 Lithium As a Treatment to Prevent Impairment of Cognition in Elders Recruiting NCT03185208 Phase 4 Lithium Carbonate;Placebo oral capsule
27 Escitalopram Effects on CSF Amyloid Beta Active, not recruiting NCT02161458 Phase 4 Escitalopram 20mg for 2 weeks;Escitalopram 20mg for 8 weeks;Escitalopram 30mg for 8 weeks;Placebo
28 Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Active, not recruiting NCT01841359 Phase 4 Pramlintide
29 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
30 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
31 Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Not yet recruiting NCT02931136 Phase 4 Huperzine A;Placebo
32 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
33 Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL Terminated NCT01450410 Phase 4 Nicotinic acid;Placebo
34 Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes Withdrawn NCT00505882 Phase 4 Pramlintide;Glargine;Lispro;Aspart
35 Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus Unknown status NCT01137695 Phase 3 Pramlintide;Pramlintide;Pramlintide;Pramlintide
36 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
37 Exenatide (Byetta) Versus Pramlintide (Symlin): Role in Post-Prandial Hyperglycemia Unknown status NCT00923715 Phase 3 Insulin;Insulin and Exenatide;Insulin and Pramlintide
38 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis Completed NCT01998503 Phase 3 Bortezomib;dexamethasone;Melphalan
39 A Trial for Systemic Light-chain (AL) Amyloidosis Completed NCT01277016 Phase 3 BMDex
40 Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
41 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
42 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis Completed NCT00344526 Phase 3 Melphalan;Dexamethasone
43 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
44 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3 dexamethasone;melphalan
45 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
46 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
47 Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain Completed NCT00857415 Phase 3 florbetapir F 18
48 Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects Completed NCT01265394 Phase 3 [18F] Flutemetamol
49 PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus Completed NCT01053312 Phase 3 [18F] Flutemetamol
50 Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology Completed NCT01020838 Phase 3 Florbetaben (BAY94-9172)

Search NIH Clinical Center for Amyloidosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: amyloidosis

Genetic Tests for Amyloidosis

Genetic tests related to Amyloidosis:

id Genetic test Affiliating Genes
1 Amyloidosis 24

Anatomical Context for Amyloidosis

MalaCards organs/tissues related to Amyloidosis:

39
Brain, Heart, Bone, Liver, Kidney, Bone Marrow, Breast

Publications for Amyloidosis

Articles related to Amyloidosis:

(show top 50) (show all 2979)
id Title Authors Year
1
Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. ( 28926601 )
2017
2
Reflectance confocal microscopy for the characterization of primary cutaneous amyloidosis: a pilot study. ( 28083882 )
2017
3
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. ( 27729322 )
2017
4
Early diagnosis of systemic amyloidosis by means of a transverse carpal ligament biopsy carried out during carpal tunnel syndrome surgery. ( 28073516 )
2017
5
Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report. ( 28802308 )
2017
6
End-stage renal failure due to transthyretin amyloidosis after liver transplantation: outcomes in 19 registry cases. ( 28434351 )
2017
7
Middle lobe syndrome: an intriguing presentation of tracheobronchial amyloidosis. ( 28536221 )
2017
8
Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis. ( 28758811 )
2017
9
Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease. ( 28295152 )
2017
10
Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm). ( 28922609 )
2017
11
Transthyretin-related hereditary amyloidosis with recurrent vomiting and renal insufficiency as the initial presentation: A case report. ( 28272196 )
2017
12
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. ( 28893208 )
2017
13
Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis. ( 28225824 )
2017
14
Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review. ( 28499374 )
2017
15
The M694I/M694I genotype: A genetic risk factor of AA-amyloidosis in a group of Algerian patients with familial Mediterranean fever. ( 27956278 )
2017
16
Systemic Amyloidosis in an African Tiger Snake (Telescopus semiannulatus). ( 28942295 )
2017
17
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. ( 28807981 )
2017
18
The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient. ( 28381753 )
2017
19
Amyloidosis: An Unusual Cause of Intestinal Pseudo-Obstruction. ( 28711693 )
2017
20
Coexistence of amyloidosis and Primary SjAPgren's Syndrome: An overview Amyloidosis and SjAPgren's syndrome. ( 28049394 )
2017
21
Detection of ALECT2 amyloidosis by positron emission tomography-computed tomography imaging with florbetapir. ( 28107549 )
2017
22
Autonomic Neuropathy and Albuminocytologic Dissociation in Cerebrospinal Fluid As the Presenting Features of Primary Amyloidosis: A Case Report. ( 28798722 )
2017
23
Clinicopathological and biochemical findings of thyroid amyloid in hereditary transthyretin amyloidosis with and without liver transplantation. ( 28081656 )
2017
24
CRYPTOCOCCUS NEOFORMANS VAR. GRUBII-ASSOCIATED RENAL AMYLOIDOSIS CAUSING PROTEIN-LOSING NEPHROPATHY IN A RED KANGAROO (MACROPUS RUFUS). ( 28920786 )
2017
25
The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. ( 28737773 )
2017
26
TGFI^ pathway deregulation and abnormal phospho-SMAD2/3 staining in hereditary cerebral hemorrhage with amyloidosis-Dutch type. ( 28557134 )
2017
27
Alitretinoin treatment of lichen amyloidosis. ( 28906049 )
2017
28
Multiple myeloma associated intestinal amyloidosis: intestinal pseudo-obstruction falsely considered as an ascites. ( 28875827 )
2017
29
Hereditary Lysozyme Amyloidosis Variant p.Leu102Ser Associates with Unique Phenotype. ( 28049649 )
2017
30
Attitudes about when and how to treat patients with AL amyloidosis: an international survey. ( 28857614 )
2017
31
Cardiac Amyloidosis Associated With Amyloidogenic Transthyretin V122I Variant in an Elderly Japanese Woman. ( 28090011 )
2017
32
Case 244: Systemic Amyloidosis-A Complication of WaldenstrAPm Macroglobulinemia. ( 28723285 )
2017
33
Lactate dehydrogenase as a prognostic marker in AL amyloidosis: expected or unexpected? ( 28737209 )
2017
34
Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. ( 28648672 )
2017
35
The First Argentinian Family with Familial Amyloidosis of the Finnish Type. ( 28924445 )
2017
36
A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. ( 28850697 )
2017
37
Marked biochemical difference in amyloid proportion between intra- and extraocular tissues in a liver-transplanted patient with hereditary ATTR amyloidosis. ( 28081655 )
2017
38
Acute heart failure by senil systemic amyloidosis: Case report. ( 28919210 )
2017
39
Comparative proteomics analysis of primary cutaneous amyloidosis. ( 28912854 )
2017
40
News in AL Amyloidosis ASH 2016: AA rapidly evolving field of investigation. ( 28725274 )
2017
41
Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma. ( 28701686 )
2017
42
An Unusual Case of Syringocystadenocarcinoma Papilliferum In Situ With Macular Amyloidosis. ( 28423161 )
2017
43
Systemic amyloidosis with gastrointestinal involvement: Diagnosis from endoscopic and histological views. ( 28940821 )
2017
44
Periocular Amyloidosis Manifesting as Pseudopemphigoid Treated With Mitomycin C. ( 28079687 )
2017
45
Unravelling hypothyroidism in AL amyloidosis: Authors' reply. ( 28861923 )
2017
46
Lichen amyloidosis involving the scalp. ( 28744954 )
2017
47
Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. ( 28832959 )
2017
48
A negative LGE is inconclusive to exclude an early cardiac amyloidosis: it's the time for a T1 mapping in clinical practice. ( 28916083 )
2017
49
Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. ( 28698204 )
2017
50
Ocular Manifestations of Familial Transthyretin Amyloidosis. ( 28911993 )
2017

Variations for Amyloidosis

Expression for Amyloidosis

Search GEO for disease gene expression data for Amyloidosis.

Pathways for Amyloidosis

Pathways related to Amyloidosis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 APP B2M CST3 FGA GSN IL31RA
2
Show member pathways
13.15 APOA1 APP B2M BACE1 CST3 FGA
3
Show member pathways
12.86 APOA1 APP B2M BACE1 CST3 FGA
4
Show member pathways
11.69 APP MEFV NLRP3
5
Show member pathways
11.63 APOA1 APOE SAA1
6 11.32 APP BACE1 TNFRSF1A
7 11.15 APOE APP BACE1
8 10.75 APP BACE1 CST3
9 10.52 APP SAA1

GO Terms for Amyloidosis

Cellular components related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.91 APOA1 APP B2M BACE1 FGA TNFRSF1A
2 axon GO:0030424 9.85 APP BACE1 CST3 IL31RA
3 extracellular region GO:0005576 9.83 APOA1 APOE APP B2M CST3 FGA
4 blood microparticle GO:0072562 9.81 APOA1 APOE FGA GSN
5 endoplasmic reticulum lumen GO:0005788 9.8 APOA1 APOE APP B2M BACE1 CST3
6 tertiary granule lumen GO:1904724 9.67 B2M CST3 LYZ
7 extracellular vesicle GO:1903561 9.65 APOA1 APOE FGA
8 high-density lipoprotein particle GO:0034364 9.55 APOA1 APOE SAA1 SAA2 SAA4
9 low-density lipoprotein particle GO:0034362 9.54 APOA1 APOE
10 endocytic vesicle lumen GO:0071682 9.54 APOA1 APOE SAA1
11 chylomicron GO:0042627 9.52 APOA1 APOE
12 extracellular space GO:0005615 9.5 APOA1 APOE APP B2M CST3 FGA
13 intermediate-density lipoprotein particle GO:0034363 9.46 APOA1 APOE
14 discoidal high-density lipoprotein particle GO:0034365 9.1 APOA1
15 extracellular exosome GO:0070062 10.13 APOA1 APOE APP B2M CST3 FGA

Biological processes related to Amyloidosis according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.99 B2M CST3 GSN LYZ TTR
2 immune system process GO:0002376 9.98 B2M FGA IL31RA MEFV NLRP3
3 apoptotic process GO:0006915 9.95 APP CST3 GSN IAPP NLRP3 TNFRSF1A
4 extracellular matrix organization GO:0030198 9.83 APP FGA TGFBI TTR
5 post-translational protein modification GO:0043687 9.8 APOA1 APOE APP CST3 FGA
6 cholesterol metabolic process GO:0008203 9.79 APOA1 APOE APP
7 retinoid metabolic process GO:0001523 9.67 APOA1 APOE TTR
8 defense response GO:0006952 9.67 CST3 IL31RA NLRP3 TNFRSF1A
9 reverse cholesterol transport GO:0043691 9.63 APOA1 APOE
10 innate immune response GO:0045087 9.63 APP B2M FGA MEFV NLRP3 SAA1
11 high-density lipoprotein particle remodeling GO:0034375 9.62 APOA1 APOE
12 high-density lipoprotein particle assembly GO:0034380 9.62 APOA1 APOE
13 phospholipid efflux GO:0033700 9.61 APOA1 APOE
14 negative regulation of interleukin-1 beta secretion GO:0050713 9.6 APOA1 NLRP3
15 chylomicron assembly GO:0034378 9.58 APOA1 APOE
16 positive regulation of cholesterol esterification GO:0010873 9.57 APOA1 APOE
17 chylomicron remodeling GO:0034371 9.56 APOA1 APOE
18 high-density lipoprotein particle clearance GO:0034384 9.55 APOA1 APOE
19 amyloid fibril formation GO:1990000 9.54 APP GSN
20 neuron projection regeneration GO:0031102 9.51 APOA1 APOE
21 positive chemotaxis GO:0050918 9.5 SAA1 SAA2 SAA4
22 regulation of Cdc42 protein signal transduction GO:0032489 9.46 APOA1 APOE
23 cellular protein metabolic process GO:0044267 9.44 APOA1 APOE APP B2M BACE1 CST3
24 lipoprotein biosynthetic process GO:0042158 9.43 APOA1 APOE
25 acute-phase response GO:0006953 9.43 SAA1 SAA2 SAA4
26 negative regulation of inflammatory response GO:0050728 9.43 APOA1 APOE MEFV NLRP3 SAA1 TNFRSF1A

Molecular functions related to Amyloidosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cholesterol transporter activity GO:0017127 9.37 APOA1 APOE
2 chemoattractant activity GO:0042056 9.33 SAA1 SAA2 SAA4
3 lipoprotein particle binding GO:0071813 9.32 APOA1 APOE
4 identical protein binding GO:0042802 9.28 APOA1 APOE APP B2M CST3 IAPP
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.26 APOA1 APOE
6 beta-amyloid binding GO:0001540 9.26 APOA1 APOE BACE1 CST3

Sources for Amyloidosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....